Paolo Manca

Fondazione IRCCS Istituto Nazionale dei Tumori

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (12)

Roberto Bei

ITALY

View details

Laura Cattaneo

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

BENEDETTA MUSSOLIN

Candiolo Cancer Institute, FPO-IRCCS

ITALY

View details

Marzia Del Re

University of Pisa

ITALY

View details

Priyadarshini Mamindla

University of Pittsburgh

UNITED STATES

View details

Kjersti Flatmark

Oslo University Hospital

NORWAY

View details

ALICE BARTOLINI

Candiolo Cancer Institute, FPO-IRCCS

ITALY

View details

Alessandra Zingoni

ITALY

View details

Carsten Krieg

Assistant Professor of Immunology

Medical University of South Carolina

UNITED STATES

View details

Chiara Cremolini

University Hospital of Pisa

ITALY

View details

Antonia Martinetti

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Giuseppe Perrone

Università Campus Bio-Medico di Roma

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paolo Manca

Research Interests

Explore related searches

Contact this professor

Articles (10)

Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers.

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Large−Scale Profiling of Extracellular Vesicles Identified miR−625−5p as a Novel Biomarker of Immunotherapy Response in Advanced Non−Small−Cell Lung Cancer Patients

ALK Inhibitors in Patients with ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series

Negative Ultraselection of Patients with RAS / BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy

Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer

EGFR Amplification in Metastatic Colorectal Cancer

Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.

Collaborators (12)

Roberto Bei

Laura Cattaneo

BENEDETTA MUSSOLIN

Marzia Del Re

Priyadarshini Mamindla

Kjersti Flatmark

ALICE BARTOLINI

Alessandra Zingoni

Carsten Krieg

Chiara Cremolini

Antonia Martinetti

Giuseppe Perrone

Make your next move.